An interview with Richard Stead about the power of OSCN
PM: Richard thank you very much for your time today to help explain the work you’ve been doing.
RS: My pleasure Phil.
PM: I suppose the first question to ask is why did you look at the OSCN molecules in the first place?
RS: Our original interest was for a technology to replace Chlorine as an antibacterial wash for cut and prepared vegetables, and maybe even fresh meat. The technology worked very well--as good as was achieved by the chlorine based systems, but also a great deal safer for workers, the environment and the actual foods.
PM: So why hasn’t the food industry adopted them?
RS: Chlorine is a very cheap material. Although ours worked out to be 5 times more expensive than chlorine--and 5 times cheap is still relatively cheap—and despite the fact that the supermarkets and the processors liked the product, neither would agree to bear the additional costs. So we failed to enter the food market. I had always told the processors that if one of their workers fell into our wash water they would come out healthier than before they fell in. With this in mind I determined to use the technology to create an alternative to existing systems for pathogen elimination – an alternative to antibiotics as our first target, and then a system to remove airborne pathogens.
PM: It is clear that ‘new’ viruses pose major threats to world health, and leading scientists are regularly exclaiming that antibiotics are becoming less effective by the day. What can nature teach us?
RS: Indeed, Phil, I like to say “Nature has the answer--chemistry is the key,” and I do believe that OSCN is one of those answers.
PM: So where in the human body can one find OSCN molecules?
RS: Principally in saliva, airways, tears and mother’s milk.
PM: And what role do they play?
RS: The OSCN molecule is created on demand when necessary to destroy low levels of pathogens. We say low levels because it is to cope with those pathogens that come into our eyes or into our mouths, on our fingers or on foods. One reason our Grandmothers told us to chew our foods more was to ensure that saliva was able to get all surfaces of the food and destroy any pathogens. Maybe our modern way of eating fast food too fast is the cause of numerous stomach bugs?
Ed. For more technical details and references please refer to Professor Paul Clayton’s article ‘The age of antibiotics is coming to an end’ in issue 1, 2012 of the Aging Matters™ magazine.
PM: Do OSCN have other advantages not attributable to antibiotics?
The possibility of bacteria being able to develop resistance is almost zero
RS: OSCN do not attack healthy gut flora. Why is this important? There is a growing acknowledgement that the microflora in our gut is related to so much of our wellbeing and as a consequence, any disruption (referred to as dysbiosis) can lead to a wide range of brain/mental and bodily malfunctions. Therefore, any medication that does good- without disrupting the gut flora is a real bonus.
PM: With such benefits, why has there never been an OSCN supplement before?
RS: It is hard to explain, but I have a couple of comments: First, it is hard to cover the technology of the molecule with a patent, and this alone would stop many pharma companies from looking at the product; second is the relative short stability of the molecule. This makes it difficult to be factory-produced and bottled or encapsulated.
PM: How did you overcome this issue?
RS: With difficulty, is the short answer, but we were determined. So with a great deal of creative thinking, design and heart ache we finally achieved a system used by patients/caregivers to create the OSCN at the point/time of use
PM: What sort of conditions have OSCNs been tested against?
RS: In laboratory conditions, the list of pathogens against which OSCN has been successful is huge. We are in the middle of clinical trials against 4 different conditions, plus, a further trial for Lyme’s disease is about to start.
PM: And what have been the responses from health professionals and patients using the kit?
RS: I cannot say we have been 100% successful, but almost all users have seen positive benefits and improvements in their conditions/symptoms. Of particular success is gut dysbiosis. The removal of the overload of bad bacteria by OSCN has allowed sufferers to start to build up the good gut flora and then onto diets to rebuild their health. But the removal of the bad bacteria is essential as a first step. Gut dysbiosis is evident in almost all sufferers of chronic conditions, for example, autism, MS, chronic fatigue, and many others.
PM: How does one dose OSCN?
RS: The dosing regimens are difficult to determine. If we could know exactly how many bad bacteria were present then a very accurate dosing schedule could be created. But until we have fast identity of the pathogen and measurement of bacterial loads, dosing has to be based upon a clinicians experience and knowledge of the patient. We always try to bring down pathogen levels to a level at which the immune system can take over. Therefore, if a sufferer has had the condition for a long time (e.g. for many months or even years) then a higher dose is needed than for a recent infection. For people prone to regular infections, then maybe a monthly maintenance dose is an idea to consider. The effect would be to regularly reduce the build-up of pathogens that are always invading us and getting past our defences, but which are not yet at a level to cause symptoms.
PM: Have there been any side-effects or contraindications?
RS: None known in the low doses used. However, a good side effect identified often by chronic sufferers has been the Herxheimer reaction – that of the liver being overloaded by the poisons given off by dying and dead pathogens, killed by the OSCN. This good sign of efficacy lasts but a short time and most practitioners/clinicians can prepare the patient/liver in advance.
PM: Some of the literature has suggested that OSCNs can have a slight lowering effect on the thyroid, would you care to comment on that?
RS: Yes, we have read the papers. Our opinion is that it’s not affected in the doses that we advocate, i.e. one or two kits/ 25/50 mg per day. But those concerned can easily offset this by adding a few drops of iodine daily, if they wish, or as is suggested by their practitioner.
PM: Are there any other steps that folks can take along with OSCN to make the program synergistic?
RS: We recognise that the effect of OSCN is to destroy pathogens. That on its own does not make the patient healthy. There is no residual effect after our molecule has been used and the patient could remain open to the same pathogen or other pathogens unless they take steps to improve their health and immune competence. This is an important aspect of working with Practitioners and clinicians. We are all different as individuals and so require different diets to bring us back to good health. Phil, just before we finish, I am very excited about our trials that are near to their conclusion and hope that the results are good and that we will then be able to present one or more papers to medical magazines for them to publish. If the results are good, we will of course let you know, and then we will start new trials on other conditions and my idea is to look at airways and topical conditions. Maybe your readers have suggestions together with guidance where we can find support groups of sufferers of a particular condition willing to find new treatments?
PM: That’s very exciting, I am sure that our readers will want to know their details when they become available.
RS: It will be my pleasure to report once they are published, and thanks for allowing me this chance to talk about OSCN, the prospects for which I find so exciting.
PM: Thank you very much.